Close Menu

expansion

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

The new Qlucore Diagnostics software builds on the recently updated Qlucore Omics Explorer platform, initially to help clinicians diagnose and treat leukemia.

Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.

The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.

The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.

Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

LifeOmic, founded less than a year ago, expects omic data sets to become as clinically relevant as diagnostic medical imaging.

Pages

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.